Sign In
Buy GMED
$80.04
+0.90 (+1.14%)
At Close: Jun 23, 2026
GMED vs. PEN: Which Stock Should Value Investors Buy Now?
12:41pm, Monday, 22'nd Jun 2026
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better
Here's How Macro Trends and Currency Headwind Restrict GMED's Growth
11:31am, Monday, 22'nd Jun 2026
Globus Medical faces inflation, geopolitical and currency pressures as rising costs and FX losses cloud margin flexibility and international growth.
Globus Medical (GMED) Surges 5.1%: Is This an Indication of Further Gains?
07:40am, Monday, 22'nd Jun 2026
Globus Medical (GMED) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increas
Here's How Innovation Fuels Globus Medical's Growth Momentum
11:36am, Monday, 15'th Jun 2026
GMED is accelerating product launches, FDA clearances and R&D investment, reinforcing its strategy to expand spine and orthopedic workflows.
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
08:00am, Friday, 12'th Jun 2026
BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its res
Here's How GMED Is Capitalizing on the Musculoskeletal Market Boom
11:06am, Tuesday, 09'th Jun 2026
Globus Medical is riding on musculoskeletal market growth with strong Q1 sales gains, double-digit spine growth, and rising trauma demand across key product lines.
Does Globus Medical (GMED) Have the Potential to Rally 38.85% as Wall Street Analysts Expect?
10:56am, Monday, 08'th Jun 2026
The consensus price target hints at a 38.9% upside potential for Globus Medical (GMED). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
GMED or PEN: Which Is the Better Value Stock Right Now?
12:40pm, Friday, 05'th Jun 2026
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for th
Here's Why Globus Medical (GMED) is a Strong Value Stock
10:40am, Friday, 05'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's How Financial Strength Remains a Key Advantage for GMED
12:55pm, Thursday, 04'th Jun 2026
Globus Medical's debt-free balance sheet, nearly $630M in liquid assets and strong cash flow give it the flexibility to fund growth and support shareholders.
Should You Buy, Hold or Sell GMED Stock Amid Musculoskeletal Boom?
11:30am, Tuesday, 02'nd Jun 2026
Globus Medical is riding musculoskeletal market growth with spine, trauma and ortho gains, strong cash flow and a debt-free balance sheet.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Globus Medical, Inc. (NYSE: GMED)
09:05am, Monday, 01'st Jun 2026
NEW YORK, June 1, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Globus Medical, Inc. (NYSE: GMED) on behalf of the company's shareholders. The investigation seeks t
GMED's Robotics Leasing Shift Could Build Recurring Revenue
10:55am, Friday, 29'th May 2026
Globus Medical is shifting robotics deals to leases and rentals, aiming to expand its installed base and build recurring revenue streams.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
02:01pm, Thursday, 28'th May 2026
TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.
GMED Growth Drivers After NuVasive and What Q1 Signals
10:26am, Thursday, 28'th May 2026
Globus Medical's Q1 showed margin gains, strong spine and trauma growth, and rising robotics adoption as NuVasive synergies support 2026 targets.
